August 28, 2014 5:12 AM ET

Biotechnology

Company Overview of Melinta Therapeutics, Inc.

Executive Profile

Mark W. Leuchtenberger

Chief Executive Officer, President and Director, Acusphere, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 6 different industries.

See Board Relationships
57--

Background

Mr. Mark W. Leuchtenberger has been the Chief Executive Officer and President at Acusphere, Inc., since September 2013. Mr. Leuchtenberger served as the President of Melinta Therapeutics, Inc. since March 23, 2010 and served as its Chief Executive Officer since March 23, 2010. He is a co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc. Before joining Acusphere in 2013, Mr. Leuchtenberger served as President and Chief Executive Officer at Rib-X Pharmaceuticals ...

Corporate Headquarters

300 George Street
New Haven, Connecticut 06511-6663

United States

Phone: 203-624-5606
Fax: 203-624-5627

Board Members Memberships

Former Chief Executive Officer, President and Director
Director
Director
2004-Present
Director, Chairman of Compensation Committee and Member of Nominating & Governance Committee
2006-2009
Former Chief Executive Officer, President and Executive Director
2010-N/A
President and Director
2013-Present
Chief Executive Officer, President and Director
2014-Present
Non-Executive Chairman

Education

MBA
Yale University
BA
Wake Forest University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Robert J. Hugin MBAChairman, Chief Executive Officer and Chairman of Executive Committee
Celgene Corporation
$1.3M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Melinta Therapeutics, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.